Aging is characterized by features such as wrinkling, loss of elasticity, sagging and a combination of reduced facial fullness and progressive bone resorption.1
Collagen content we lose in our skin per year from age 204
Sculptra patients who reported ongoing improvement in skin firmness7
Skin firming treatments
Discover the benefits of Sculptra®, the first proven regenerative biostimulator that addresses different skin concerns.8-13
Immediately boost skin quality for smooth, even, younger-looking, and glowing skin.14-27
Achieve a look that is uniquely yours with a diverse range of hyaluronic acid dermal fillers.28-35
Find a clinic
Learn how you can reduce signs of aging and return
to firmer skin.
1. Zhang S, Duan E. Cell Transplantation (2018);27(5):729-738. 2. Aziz J, et al. Skin Pharmacol Physiol. 2016;29(4):190–203. 3. Swift A, et al, Aesthet Surg J. 2021;41(10):1107–19. 4. Shuster S, Black M et al. Br J Dermatol. 1975;93(6):639–43. 13. 5. Vleggaar D, Fitzgerald R. J Drugs Dermatol. 2008;7(3):209–20. 6. Dermatological implications of skeletal aging: a focus on supraperiosteal volumization for perioral rejuvenation. 7. Fabi S, et al. Poster presented at IMCAS. 26–28 January 2023. Paris, France. 8. Sculptra. Instructions for Use EU 2021.
9. Galderma Receives FDA Approval for New SCULPTRA® Label, Offering More Options to Aesthetic Partners. Galderma. 2021. Available from: https://www.galderma.com/news/galderma-receives-fda-approvalnew-sculptra-label-offering-more-options-aesthetic-partners [Last accessed June 2024]. 10. Asius J, et al. US patent US 7,731,758 B22(010):2010. 11. Sanofi S.r.l. DEKRA EN ISO 13485:2016 Certificate. Certificate effective since: February 2023. 12. Zhang Y, et al. Regen Biomater 2021;8(5):rbab042.
13. Widgerow A, et al. A randomized, comparative study describing the gene signatures of poly-l-lactic acid (PLLA-SCA) and calcium hydroxylapaptite (CaHA) in the treatment of nasolabial folds. Poster presented at IMCAS. 1–3 February 2024. 14. Williams S et al. J Cosmet Dermatol. 2009;8(3):216–225. 15. Nikolis A et al. Clin Cosmet Investig Dermatol. 2018;11:467–475. 16. Kim J. Arch Aesthetic Plast Surg. 2014;20(2):97–103. 17. Distante F et al. Dermatol Surg. 2009;35 Suppl 1:389–393. 18. Nikolis A, Enright KM. J Dermatol Skin Sci. 2020;2(1):26–28.
19. Gubanova EI et al. J Drugs Dermatol. 2015;14(3):288–299. 20. Gubanova EI et al. Aesthetic Med. 2010;1:94–98. 21. Wu Y et al. J Cosmet Dermatol. 2020;19(7):1627–1635. 22. Willkerson EC, Goldberg DJ. Dermatol Surg. 2018;44(1):68–74. 23. Streker M et al. J Drugs Dermatol. 2013;12(9):990–994. 24. Dierickx C et al. Dermatol Surg. 2018;44 Suppl 1:S10–S18. 25. Lee BM et al. Arch Plast Surg. 2015;42(3):282–287. 26. Gubanova EI et al. Poster presented at IMCAS, Jan–Feb 2015, Paris, France. 27. Data on file MA-54615. Restylane SKINBOOSTERS Competitor Comparison. 28. Data on file MA-43049. 29. Restylane® Lyft™ EU IFU. 30. Restylane® Kysse™ EU IFU. 31. Restylane® Volyme™ EU IFU. 32. Restylane® Refyne™ EU IFU. 33. Restylane® Defyne™ EU IFU. 34. Restylane® Eyelight™ EU IFU. 35. Restylane® EU IFU.
Always consult a healthcare professional for individualized treatment recommendations and to discuss important safety information and risks associated with the use of the products.